A propensity-matched analysis of stereotactic body radiotherapy and sublobar resection for stage I non-small cell lung cancer in patients at high risk for lobectomy: the results in a Chinese population

doi:10.21037/jtd-21-339

	A propensity-matched analysis of stereotactic body radiotherapy and sublobar resection for stage I non-small cell lung cancer in patients at high risk for lobectomy: the results in a Chinese population
	Yuan, Xiao-Shuai 2; Chen, Wu-Cheng 3; Lin, Qing-Ren 1; Liu, Yuan-Jun 1; Zhu, Yao-Yao 2; Sun, Xiao-Jiang 3; Wu, Qiong-Ya 2; Liu, Jin-Shi 4; Xu, Ya-Ping 1,2,3
刊名	JOURNAL OF THORACIC DISEASE
	2021-03-01
卷号	13
关键词	Non-small cell lung cancer (NSCLC) stereotactic body radiotherapy (SBRT) sublobar resection (SLR) propensity score
ISSN号	2072-1439
DOI	10.21037/jtd-21-339
通讯作者	Wu, Qiong-Ya(wqyluj@sohu.com) ; Liu, Jin-Shi(yefeng9725boy@163.com) ; Xu, Ya-Ping(dr_xuyaping@163.com)
英文摘要	Background: To investigate the comparative effectiveness of stereotactic body radiotherapy (SBRT) and sublobar resection (SLR) in patients with stage I non-small cell lung cancer (NSCLC) considered to be highrisk lobectomy patients. Methods: From January 2012 to December 2015, patients who underwent SBRT or SLR for clinical stage I NSCLC were examined retrospectively. Propensity score matching (PSM) was performed to reduce selection bias in SBRT and SLR patients. Results: Data from 86 SBRT and 79 SLR patients was collected. Median follow-up periods of the SBRT and SLR groups were 32 and 37 months, respectively. Patients treated with SBRT exhibited significantly higher age, higher likelihood of being male, larger tumor diameter, lower forced expiratory volume in 1 second (FEV1), and poorer performance status compared with SLR patients. There were no significant differences between SBRT and SLR patients for 3-year overall survival (OS) (80.3% and 82.3%, P=0.405), cause-specific survival (CSS) (81.3% and 83.4%, P=0.383), and local control (LC) (89.7% and 86.0%, P=0.501). Forty-nine patients were identified from each group after performing PSM. After patients were matched for age, gender, performance status, tumor characteristics and pulmonary function, no significant differences were observed in 3-year OS (85.4% and 73.3%, P=0.649), CSS (87.2% and 74.9%, P=0.637) and LC (95.6% and 82.1%, P=0.055). Prevalence of significant adverse events (grade 3 or worse) was 0% and Background: To investigate the comparative effectiveness of stereotactic body radiotherapy (SBRT) and sublobar resection (SLR) in patients with stage I non-small cell lung cancer (NSCLC) considered to be high risk lobectomy patients. Methods: From January 2012 to December 2015, patients who underwent SBRT or SLR for clinical stage I NSCLC were examined retrospectively. Propensity score matching (PSM) was performed to reduce selection bias in SBRT and SLR patients. Results: Data from 86 SBRT and 79 SLR patients was collected. Median follow-up periods of the SBRT and SLR groups were 32 and 37 months, respectively. Patients treated with SBRT exhibited significantly higher age, higher likelihood of being male, larger tumor diameter, lower forced expiratory volume in 1 second (FEV1), and poorer performance status compared with SLR patients. There were no significant differences between SBRT and SLR patients for 3-year overall survival (OS) (80.3% and 82.3%, P=0.405), cause-specific survival (CSS) (81.3% and 83.4%, P=0.383), and local control (LC) (89.7% and 86.0%, P=0.501). Forty-nine patients were identified from each group after performing PSM. After patients were matched for age, gender, performance status, tumor characteristics and pulmonary function, no significant differences were observed in 3-year OS (85.4% and 73.3%, P=0.649), CSS (87.2% and 74.9%, P=0.637) and LC (95.6% and 82.1%, P=0.055). Prevalence of significant adverse events (grade 3 or worse) was 0% and 10.2% in the matched SBRT and SLR groups (P=0.056), respectively. Conclusions: Disease control and survival in the SBRT patients was equivalent to that seen in SLR patients with stage I NSCLC considered high-risk lobectomy candidates. SBRT could therefore be an alternative option to SLR in treating patients with a high operative risk.
资助项目	Science Research Foundation of China Ministry of Health - Zhejiang Medicine & Health Key Research Fund[201339868]
WOS研究方向	Respiratory System
语种	英语
出版者	AME PUBL CO
WOS记录号	WOS:000634458800011
资助机构	Science Research Foundation of China Ministry of Health - Zhejiang Medicine & Health Key Research Fund
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/121521]
专题	中国科学院合肥物质科学研究院
通讯作者	Wu, Qiong-Ya; Liu, Jin-Shi; Xu, Ya-Ping
作者单位	1.Univ Chinese Acad Sci, Canc Hosp, Dept Radiat Oncol, Hangzhou, Peoples R China 2.Tongji Univ, Dept Radiat Oncol, Shanghai Pulm Hosp, 507 Zhengmin Rd, Shanghai, Peoples R China 3.Wenzhou Med Univ, Clin Med Sch 1, Wenzhou, Peoples R China 4.Univ Chinese Acad Sci, Canc Hosp, Dept Thorac Oncol, 1 East Rd Banshan, Hangzhou, Peoples R China
推荐引用方式 GB/T 7714	Yuan, Xiao-Shuai,Chen, Wu-Cheng,Lin, Qing-Ren,et al. A propensity-matched analysis of stereotactic body radiotherapy and sublobar resection for stage I non-small cell lung cancer in patients at high risk for lobectomy: the results in a Chinese population[J]. JOURNAL OF THORACIC DISEASE,2021,13.
APA	Yuan, Xiao-Shuai.,Chen, Wu-Cheng.,Lin, Qing-Ren.,Liu, Yuan-Jun.,Zhu, Yao-Yao.,...&Xu, Ya-Ping.(2021).A propensity-matched analysis of stereotactic body radiotherapy and sublobar resection for stage I non-small cell lung cancer in patients at high risk for lobectomy: the results in a Chinese population.JOURNAL OF THORACIC DISEASE,13.
MLA	Yuan, Xiao-Shuai,et al."A propensity-matched analysis of stereotactic body radiotherapy and sublobar resection for stage I non-small cell lung cancer in patients at high risk for lobectomy: the results in a Chinese population".JOURNAL OF THORACIC DISEASE 13(2021).